The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 12, 2022

Filed:

May. 27, 2019
Applicant:

Altimmune Uk Limited, London, GB;

Inventors:
Assignee:

Altimmune UK LTD, Leeds, GB;

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/29 (2006.01); A61K 39/12 (2006.01); C12N 7/00 (2006.01); A61K 45/06 (2006.01); C07K 14/005 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/292 (2013.01); A61K 39/12 (2013.01); A61K 45/06 (2013.01); C07K 14/005 (2013.01); C12N 7/00 (2013.01); A61K 2039/55 (2013.01); A61K 2039/572 (2013.01); A61K 2039/58 (2013.01); A61K 2039/60 (2013.01); A61K 2039/70 (2013.01); C12N 2730/10122 (2013.01); C12N 2730/10134 (2013.01); C12N 2730/10171 (2013.01);
Abstract

A pharmaceutical composition comprising at least two peptides of from 15 to 60 amino acids in length, selected from peptides comprising a sequence of at least 15 contiguous amino acids of one of the sequences shown in SEQ ID NOs: 1 to 4 or of a sequence having at least 80% identity to one of the sequences shown in SEQ ID NOs: to 4, wherein each peptide comprises at least one CD8+ T-cell epitope and/or at least one CD4+ T-cell epitope and wherein each peptide elicits a response in peripheral blood mononuclear cells (BMC) from at least one chronically infected HBV individual in an 10 in vitroassay.


Find Patent Forward Citations

Loading…